|
Age in years, mean ± SD
|
29.7 ± 6.2
|
30.9 ± 5.1
|
|
Parity, n (%)
| | |
|
P0
|
38 (76%)
|
15 (65.2%)
|
|
P1
|
6 (12%)
|
5 (21.7%)
|
|
P2
|
6 (12%)
|
3 (13.1%)
|
|
rAFS score for endometriosis, median (IQR)
|
14 (10–26)
|
NA
|
|
rAFS stage for endometriosis, n (%)
| | |
|
Stage I
|
7 (14%)
|
NA
|
|
Stage II
|
19 (38%)
| |
|
Stage III
|
19 (38%)
| |
|
Stage IV
|
5 (10%)
| |
|
Serum IL-37 (pg/mL), median (IQR)
|
128.1 (93.9–198.7)
|
64.6 (52.7–94.3)
|
|
Peritoneal fluid IL-37 (pg/mL), median (IQR)
|
146.2 (106.1–194.4)
|
75.5 (61.8–108.2)
|
|
IL-37 mRNA expression, (2−ΔCT)
|
0.0239 (0.01393–0.03218)
|
0.0029 (0.0017–0.0052)
|
|
Peritoneal fluid TNF-α (pg/mL), median (IQR)
|
55.55 (39.7–63.5)
|
15.6 (12.8–19.3)
|
